Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

CTAD Boston 2017

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

CTAD 2017 will highlight the latest on trying to get these trials off the ground.

November 1 - 4 2017
Boston Park Plaza, Boston, MA

Are you attending this event?

Meet with us


Data presentations

We will be presenting 4 exciting new studies at CTAD during the poster sessions. 

Automated voice-based testing: applications in recruitment of patients in clinical trials 
Nick Taptiklis, Francesca Cormack PhD, Jennifer H Barnett PhD

Recent advances in automatic speech recognition from deep-learning-based systems have led us to consider whether it may now be possible to automate voice-based cognitive assessment.

Here we describe the development and testing of a voice-based cognitive testing battery, using Amazon’s Alexa speech recognition, and Microsoft’s speech service for web-based delivery.

A comparison of in-person and web-based computerised cognitive testing using CANTAB
Francesca Cormack, Rosa Backx, Jack Cotter, Nick Taptiklis, Lucie de Cock, Kenton Zavitz, Jennifer H Barnett

Testing individuals in their own homes and on their own devices has the potential to improve the efficiency of screening into clinical trials.

Here we present the results of two studies aimed at validating at home web-based testing against in-person assessment.

Diagnostic value of a cognitive battery for assessing cognitive decline
A. Nidos, D. Kasselimis, K. Zavitz, F. Cormack

Early diagnosis of progressive cognitive decline is a crucial issue for clinicians involved in assessment of elderly individuals. 

This study explores the clinical-diagnostic value of a brief neuropsychological battery for dementia, consisting of fully automated computerized tasks and classical neuropsychological measures of memory and language.

Enriching Participant Eligibility for Early AD Clinical Trials through Computerized Pre-Screening for Episodic Memory Deficit
Kenton Zavitz, Rosemary Abbott, Francesca Cormack, Pasquale Dente, Jennifer H Barnett

Identifying Prodromal AD patients is important in successfully implementing clinical trials of disease modifying drugs. Pre-screening on objective cognitive tests has the potential to increase the proportion of trial participants who will meet the inclusion criteria at screening and minimise costly screen failures.

Here we summarise data on the use of an objective digital cognitive test to enhance various samples for specific trial requirements.